"Novartis has completed its transformation into a pure-play innovative medicines company, with deep expertise and capabilities across our core therapeutic areas and technology platforms," indicated CEO Vas Narasimhan. This strategic refocusing has allowed Novartis to enhance its commercial execution significantly, maximizing the potential of its leading drugs and treatments under development.
"Our focus has allowed us to sharpen our commercial execution and increase our peak sales estimates for Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio, and we have more than 15 submission-enabling readouts in the coming years to further bolster our growth profile," said Narasimhan. This highlights the company's commitment to driving growth through performance improvement in its existing portfolio.
"Longer term, we've identified more than 30 assets in the pipeline with significant potential to rejuvenate our portfolio and support mid-single-digit growth post 2029," Narasimhan stated. This indicates a strong pipeline that promises to sustain growth beyond the immediate forecast period.
Collection
[
|
...
]